404 related articles for article (PubMed ID: 23934133)
1. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutics in multiple myeloma.
Stewart AK
Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Orlowski RZ
Semin Oncol; 2013 Oct; 40(5):634-51. PubMed ID: 24135408
[TBL] [Abstract][Full Text] [Related]
4. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
5. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
6. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed and refractory multiple myeloma.
Sonneveld P; Broijl A
Haematologica; 2016 Apr; 101(4):396-406. PubMed ID: 27033237
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Mitsiades CS; Hideshima T; Chauhan D; McMillin DW; Klippel S; Laubach JP; Munshi NC; Anderson KC; Richardson PG
Semin Hematol; 2009 Apr; 46(2):166-75. PubMed ID: 19389500
[TBL] [Abstract][Full Text] [Related]
9. Progress and Paradigms in Multiple Myeloma.
Anderson KC
Clin Cancer Res; 2016 Nov; 22(22):5419-5427. PubMed ID: 28151709
[TBL] [Abstract][Full Text] [Related]
10. Development of target-specific treatments in multiple myeloma.
Chanan-Khan AA; Borrello I; Lee KP; Reece DE
Br J Haematol; 2010 Oct; 151(1):3-15. PubMed ID: 20618339
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for multiple myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
[No Abstract] [Full Text] [Related]
13. Emerging agents and regimens for multiple myeloma.
Yang Y; Li Y; Gu H; Dong M; Cai Z
J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
[TBL] [Abstract][Full Text] [Related]
14. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Zhang K; Desai A; Zeng D; Gong T; Lu P; Wang M
Oncotarget; 2017 Feb; 8(6):10748-10759. PubMed ID: 27863374
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic progress in relapsed/refractory multiple myeloma.
Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
[TBL] [Abstract][Full Text] [Related]
16. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Cornell RF; Kassim AA
Bone Marrow Transplant; 2016 Apr; 51(4):479-91. PubMed ID: 26726946
[TBL] [Abstract][Full Text] [Related]
17. The pharmacologic management of multiple myeloma in older adults.
Dempsey JL; Johns A; Rosko AE; Lazarus HM
Expert Opin Pharmacother; 2019 May; 20(7):887-902. PubMed ID: 30785310
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs and combinations to treat multiple myeloma.
Larocca A; Mina R; Gay F; Bringhen S; Boccadoro M
Oncotarget; 2017 Sep; 8(36):60656-60672. PubMed ID: 28948001
[TBL] [Abstract][Full Text] [Related]
19. Immune-based therapies in the management of multiple myeloma.
Zanwar S; Nandakumar B; Kumar S
Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
[TBL] [Abstract][Full Text] [Related]
20. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
